^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xpovio (selinexor)

    i
    Other names: KPT-330, KPT-330-003, SINE KPT-330, KPT330, KPT 330, ATG-010, ONO-7705, ONO 7705, ATG010, ATG 010, ONO7705
    Company:
    Antengene, FORUS Therap, Jiangsu Hansoh Pharma, Karyopharm, Menarini, NeoPharm
    Drug class:
    XPO1 inhibitor
    Related drugs:
    2d
    Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma. (PubMed, Cancer Med)
    Venetoclax and selinexor retained activity in resistant models, supporting their potential for rational combinations with TK216. These findings demonstrate that multiple, heterogeneous mechanisms drive resistance to ETS inhibition in DLBCL, highlighting therapeutic strategies to overcome it.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • AURKA (Aurora kinase A) • SPI1 (Spi-1 Proto-Oncogene)
    |
    Venclexta (venetoclax) • Xpovio (selinexor) • ONCT-216
    5d
    Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=62, Recruiting, Natalie Callander | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Xpovio (selinexor) • carfilzomib • dexamethasone injection • isatuximab subcutaneous (SAR650984 SC)
    7d
    A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=261, Recruiting, Shandong New Time Pharmaceutical Co., LTD
    New P3 trial • Head-to-Head
    |
    bortezomib • Xpovio (selinexor) • dexamethasone • pomalidomide • F182112
    11d
    A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Tyvyt (sintilimab) • Xpovio (selinexor) • Oncaspar liquid (pegaspargase)
    11d
    Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. (PubMed, Expert Opin Pharmacother)
    Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xpovio (selinexor) • Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib) • pelabresib (DAK539) • elritercept (KER-050)
    13d
    KCP-330-009: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P2, N=244, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> Dec 2026 | Trial primary completion date: Apr 2027 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Xpovio (selinexor)
    13d
    A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2/3, N=501, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone
    13d
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=260, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • TQB2934
    15d
    STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)
    P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    16d
    Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma. (PubMed, Neuro Oncol)
    Our findings demonstrate that ZR interacting proteins constitute therapeutic leads, and that XPO1 is critical for titrating 'goldilocks' levels of ZR nuclear expression. We identify a novel combination therapy of Selinexor, Gemcitabine, and Ribociclib that may be immediately translated into clinical trials for EPN patients that are currently without targeted treatments.
    Journal • IO biomarker
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDK1 (Cyclin-dependent kinase 1) • RELA (RELA Proto-Oncogene) • ZFTA (Zinc Finger Translocation Associated)
    |
    gemcitabine • Kisqali (ribociclib) • Xpovio (selinexor)
    16d
    Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation. (PubMed, Clin Transl Med)
    XPO1 hyperactivation rewires nucleocytoplasmic transport and sustains leukaemogenic programs in genetically defined acute myeloid leukaemia (AML) subsets. Selective XPO1 inhibitors (selinexor, eltanexor) show preferential activity in NPM1-mutated, DEK::NUP214-positive and SF3B1-mutated myeloid neoplasms. Combination strategies with hypomethylating agents, BCL-2 inhibitors and other targeted therapies enhance depth and durability of responses but are limited by toxicity. Future clinical trials should focus on molecularly selected populations, biomarker-guided dosing and translational endpoints such as measurable residual disease (MRD) and clonal dynamics.
    Review • Journal • IO biomarker
    |
    NPM1 (Nucleophosmin 1) • SF3B1 (Splicing Factor 3b Subunit 1) • NUP214 (Nucleoporin 214) • XPO1 (Exportin 1)
    |
    NPM1 mutation • SF3B1 mutation
    |
    Venclexta (venetoclax) • Xpovio (selinexor) • eltanexor (KPT-8602)
    21d
    Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    gemcitabine • oxaliplatin • Xpovio (selinexor) • Oncaspar liquid (pegaspargase)